1. Home
  2. YRD vs DSGN Comparison

YRD vs DSGN Comparison

Compare YRD & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yiren Digital Ltd.

YRD

Yiren Digital Ltd.

HOLD

Current Price

$3.98

Market Cap

407.8M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.70

Market Cap

504.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YRD
DSGN
Founded
2012
2017
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
407.8M
504.7M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
YRD
DSGN
Price
$3.98
$9.70
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
58.8K
493.9K
Earning Date
11-25-2025
11-05-2025
Dividend Yield
10.71%
N/A
EPS Growth
N/A
N/A
EPS
2.03
N/A
Revenue
$872,820,262.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.03
N/A
Revenue Growth
10.41
N/A
52 Week Low
$4.02
$2.60
52 Week High
$8.74
$10.31

Technical Indicators

Market Signals
Indicator
YRD
DSGN
Relative Strength Index (RSI) 27.58 57.01
Support Level $4.02 $9.44
Resistance Level $4.41 $10.08
Average True Range (ATR) 0.14 0.64
MACD 0.00 -0.05
Stochastic Oscillator 16.39 69.88

Price Performance

Historical Comparison
YRD
DSGN

About YRD Yiren Digital Ltd.

Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: